Cargando…

Fructosamine-3-Kinase as a Potential Treatment Option for Age-Related Macular Degeneration

Age-related macular degeneration is the leading cause of blindness in the developed world. Since advanced glycation end products (AGEs) are implicated in the pathogenesis of AMD through various lines of evidence, we investigated the potential of fructosamine-3-kinase (FN3K) in the disruption of reti...

Descripción completa

Detalles Bibliográficos
Autores principales: De Bruyne, Sander, Van den Broecke, Caroline, Vrielinck, Henk, Khelifi, Samira, De Wever, Olivier, Bracke, Ken, Huizing, Manon, Boston, Nezahat, Himpe, Jonas, Speeckaert, Marijn, Vral, Anne, Van Dorpe, Jo, Van Aken, Elisabeth, Delanghe, Joris R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565857/
https://www.ncbi.nlm.nih.gov/pubmed/32899850
http://dx.doi.org/10.3390/jcm9092869
_version_ 1783596024771641344
author De Bruyne, Sander
Van den Broecke, Caroline
Vrielinck, Henk
Khelifi, Samira
De Wever, Olivier
Bracke, Ken
Huizing, Manon
Boston, Nezahat
Himpe, Jonas
Speeckaert, Marijn
Vral, Anne
Van Dorpe, Jo
Van Aken, Elisabeth
Delanghe, Joris R.
author_facet De Bruyne, Sander
Van den Broecke, Caroline
Vrielinck, Henk
Khelifi, Samira
De Wever, Olivier
Bracke, Ken
Huizing, Manon
Boston, Nezahat
Himpe, Jonas
Speeckaert, Marijn
Vral, Anne
Van Dorpe, Jo
Van Aken, Elisabeth
Delanghe, Joris R.
author_sort De Bruyne, Sander
collection PubMed
description Age-related macular degeneration is the leading cause of blindness in the developed world. Since advanced glycation end products (AGEs) are implicated in the pathogenesis of AMD through various lines of evidence, we investigated the potential of fructosamine-3-kinase (FN3K) in the disruption of retinal AGEs, drusenoid material and drusenoid lesions in patients with AMD. AGE-type autofluorescence was measured to evaluate the effects of FN3K on glycolaldehyde-induced AGE-modified neural porcine retinas and unmodified human neural retinas. Eye pairs from cigarette-smoke- and air-exposed mice were treated and evaluated histologically. Automated optical image analysis of human tissue sections was performed to compare control- and FN3K-treated drusen and near-infrared (NIR) microspectroscopy was performed to examine biochemical differences. Optical coherence tomography (OCT) was used to evaluate the effect of FN3K on drusenoid deposits after treatment of post-mortem human eyes. FN3K treatment provoked a significant decrease (41%) of AGE-related autofluorescence in the AGE-modified porcine retinas. Furthermore, treatment of human neural retinas resulted in significant decreases of autofluorescence (−24%). FN3K-treated murine eyes showed less drusenoid material. Pairwise comparison of drusen on tissue sections revealed significant changes in color intensity after FN3K treatment. NIR microspectroscopy uncovered clear spectral differences in drusenoid material (Bruch’s membrane) and drusen after FN3K treatment. Ex vivo treatment strongly reduced size of subretinal drusenoid lesions on OCT imaging (up to 83%). In conclusion, our study demonstrated for the first time a potential role of FN3K in the disruption of AGE-related retinal autofluorescence, drusenoid material and drusenoid lesions in patients with AMD.
format Online
Article
Text
id pubmed-7565857
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75658572020-10-26 Fructosamine-3-Kinase as a Potential Treatment Option for Age-Related Macular Degeneration De Bruyne, Sander Van den Broecke, Caroline Vrielinck, Henk Khelifi, Samira De Wever, Olivier Bracke, Ken Huizing, Manon Boston, Nezahat Himpe, Jonas Speeckaert, Marijn Vral, Anne Van Dorpe, Jo Van Aken, Elisabeth Delanghe, Joris R. J Clin Med Article Age-related macular degeneration is the leading cause of blindness in the developed world. Since advanced glycation end products (AGEs) are implicated in the pathogenesis of AMD through various lines of evidence, we investigated the potential of fructosamine-3-kinase (FN3K) in the disruption of retinal AGEs, drusenoid material and drusenoid lesions in patients with AMD. AGE-type autofluorescence was measured to evaluate the effects of FN3K on glycolaldehyde-induced AGE-modified neural porcine retinas and unmodified human neural retinas. Eye pairs from cigarette-smoke- and air-exposed mice were treated and evaluated histologically. Automated optical image analysis of human tissue sections was performed to compare control- and FN3K-treated drusen and near-infrared (NIR) microspectroscopy was performed to examine biochemical differences. Optical coherence tomography (OCT) was used to evaluate the effect of FN3K on drusenoid deposits after treatment of post-mortem human eyes. FN3K treatment provoked a significant decrease (41%) of AGE-related autofluorescence in the AGE-modified porcine retinas. Furthermore, treatment of human neural retinas resulted in significant decreases of autofluorescence (−24%). FN3K-treated murine eyes showed less drusenoid material. Pairwise comparison of drusen on tissue sections revealed significant changes in color intensity after FN3K treatment. NIR microspectroscopy uncovered clear spectral differences in drusenoid material (Bruch’s membrane) and drusen after FN3K treatment. Ex vivo treatment strongly reduced size of subretinal drusenoid lesions on OCT imaging (up to 83%). In conclusion, our study demonstrated for the first time a potential role of FN3K in the disruption of AGE-related retinal autofluorescence, drusenoid material and drusenoid lesions in patients with AMD. MDPI 2020-09-04 /pmc/articles/PMC7565857/ /pubmed/32899850 http://dx.doi.org/10.3390/jcm9092869 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
De Bruyne, Sander
Van den Broecke, Caroline
Vrielinck, Henk
Khelifi, Samira
De Wever, Olivier
Bracke, Ken
Huizing, Manon
Boston, Nezahat
Himpe, Jonas
Speeckaert, Marijn
Vral, Anne
Van Dorpe, Jo
Van Aken, Elisabeth
Delanghe, Joris R.
Fructosamine-3-Kinase as a Potential Treatment Option for Age-Related Macular Degeneration
title Fructosamine-3-Kinase as a Potential Treatment Option for Age-Related Macular Degeneration
title_full Fructosamine-3-Kinase as a Potential Treatment Option for Age-Related Macular Degeneration
title_fullStr Fructosamine-3-Kinase as a Potential Treatment Option for Age-Related Macular Degeneration
title_full_unstemmed Fructosamine-3-Kinase as a Potential Treatment Option for Age-Related Macular Degeneration
title_short Fructosamine-3-Kinase as a Potential Treatment Option for Age-Related Macular Degeneration
title_sort fructosamine-3-kinase as a potential treatment option for age-related macular degeneration
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565857/
https://www.ncbi.nlm.nih.gov/pubmed/32899850
http://dx.doi.org/10.3390/jcm9092869
work_keys_str_mv AT debruynesander fructosamine3kinaseasapotentialtreatmentoptionforagerelatedmaculardegeneration
AT vandenbroeckecaroline fructosamine3kinaseasapotentialtreatmentoptionforagerelatedmaculardegeneration
AT vrielinckhenk fructosamine3kinaseasapotentialtreatmentoptionforagerelatedmaculardegeneration
AT khelifisamira fructosamine3kinaseasapotentialtreatmentoptionforagerelatedmaculardegeneration
AT deweverolivier fructosamine3kinaseasapotentialtreatmentoptionforagerelatedmaculardegeneration
AT brackeken fructosamine3kinaseasapotentialtreatmentoptionforagerelatedmaculardegeneration
AT huizingmanon fructosamine3kinaseasapotentialtreatmentoptionforagerelatedmaculardegeneration
AT bostonnezahat fructosamine3kinaseasapotentialtreatmentoptionforagerelatedmaculardegeneration
AT himpejonas fructosamine3kinaseasapotentialtreatmentoptionforagerelatedmaculardegeneration
AT speeckaertmarijn fructosamine3kinaseasapotentialtreatmentoptionforagerelatedmaculardegeneration
AT vralanne fructosamine3kinaseasapotentialtreatmentoptionforagerelatedmaculardegeneration
AT vandorpejo fructosamine3kinaseasapotentialtreatmentoptionforagerelatedmaculardegeneration
AT vanakenelisabeth fructosamine3kinaseasapotentialtreatmentoptionforagerelatedmaculardegeneration
AT delanghejorisr fructosamine3kinaseasapotentialtreatmentoptionforagerelatedmaculardegeneration